Launch of Next-Generation Dialysis Water Treatment System "MOLSEP® FC-HE" Series

Achieves Significant Size Reduction Through Integrated Development of New Membrane and System

DAISEN MEMBRANE SYSTEMS CO., LTD. (Headquarters: Minato-ku, Tokyo; President: Masayoshi Yasuhara) has announced the launch of its new dialysis water treatment system, the"MOLSEP® FC-HE Series," for medical institutions and medical device manufacturers.

This product is a next-generation water treatment system based on the company's long-cultivated membrane technology and incorporates a newly developed high-recovery reverse osmosis (RO) module. It achieves both the high water quality required for dialysis treatment and reductions in installation space and operating costs.

Major Reduction in Size Compared with Conventional and Competing Systems

The FC-HE Series adopts a newly designed high-recovery RO module and optimizes the internal structure of the system. As a result, compared with previous models:

• Width reduced by approximately 50 mm
• Depth reduced by approximately 70 mm
• Overall size reduced by about 10%

This delivers exceptional space efficiency compared not only with previous company models but also with competing systems.

The compact design improves installation flexibility in limited machine room spaces and enables medical facilities to better accommodate layout optimization, upgrades, and expansions.

Compact Design Enabled by Integrated Development of Membrane and System

A key feature of this product is the company's unique capability to handle membrane development, system design, and manufacturing in an integrated manner.

In typical water treatment systems, membrane and equipment manufacturers are separate, which limits optimization in system design. In contrast, DAISEN MEMBRANE SYSTEMS achieves simultaneous optimization of membrane performance and system structure, enabling:

• High recovery rates (75-80%) with energy efficiency
• Compact system design through elimination of unnecessary internal structure
• Stable water quality and high reliability

This "membrane × system" integrated approach is the primary factor behind achieving both superior compactness and high performance compared with conventional products and competitors.

Comprehensive Features to Address Challenges in Medical Settings

In addition to improving space efficiency, the FC-HE Series enhances operational efficiency and safety in medical environments:

• Remote monitoring system for visualizing equipment status
• Guidance functions to simplify maintenance tasks
• Optional UF (ultrafiltration) membrane systems (UX system & ET system) for endotoxin reduction
• Energy-saving operation to reduce electricity and water costs
• Newly designed boost operation activated only during cleaning, enabling compact design tailored to normal water usage

The high recovery-rate design also reduces water consumption and contributes to lowering environmental impact.

Main Applications

• Dialysis water production in hospitals and dialysis clinics
• System applications for medical device manufacturers

The company also plans to expand into pure water systems for general industrial use by leveraging the compactness and cost advantages of the product.

Future Outlook

DAISEN MEMBRANE SYSTEMS will continue to create unique value through the integration of membrane technology and system design, contributing to its social mission of "Save the PEOPLE" by ensuring safe and reliable water supply in the medical field.

As of April 1, 2026, the company has joined Daicel Corporation's Life Science Strategic Business Unit (SBU), strengthening group-wide expansion in the medical and life sciences fields.

Demonstration Unit

The company exhibited the MOLSEP® FC-HE Series at the 71st Annual Meeting of the Japanese Society for Dialysis Therapy. Attendees provided positive feedback such as:

• "Extremely compact"
• "The touchscreen maintenance guidance is very helpful"
• "We would like to adopt it during our next system upgrade"

(Note: Comparisons in compact design with the company's and competitors' products are based on internal research.)